Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

Leukemia

Volumn 13, Issue 2, 1999, Pages 258-265

  Broxterman, H J ^a   Sonneveld, P ^b   Pieters, R ^a   Lankelma, J ^a   Eekman, C A ^a   Loonen, A H ^a   Schoester, M ^b   Ossenkoppele, G J ^a   Lowenberg B ^b   Pinedo, H M ^a   Schuurhuis, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Acute myeloid leukemia; Daunorubicin; LRP; Major vault protein; MTT assay; Multidrug resistance; P glycoprotein

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; DAUNORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; RHODAMINE 123; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; DRUG TRANSPORT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033031280     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401331     Document Type: Article

References (34)

1. Baer MR, Bloomfield CD. Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 663-665.
2. Bosanquet AG. Correlations between therapeutic response of leukaemias and in vitro drug-sensitivity assay. Lancet 1991; 337: 711-714.
3. Nagourney RA. Multidrug resistance in acute leukemia. J Natl Cancer Inst 1991; 83: 1418.
4. Löwenberg B, van Putten WLJ, Touw IP, Delwel R, Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. New Engl J Med 1993; 328: 614-619.
5. Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 1989; 60: 206-210.
6. Pieters R, Huismans DR, Loonen AH, Hählen K, van der Doesvan den Burg A, van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399-403.
7. Kaspers GJL, Veerman AJP, Pieters R, van Zantwijk CH, Smets LA, van Wering ER, van der Does-van den Berg A. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723-2729.
8. Kokenberg E, Sonneveld P, Delwel R, Sizoo W, Hagenbeek A, Löwenberg B. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 1988; 2: 511-517.
9. Kessel D, Wilberding C, Karanes C, Ratanatharathorn V. Daunorubicin accumulation by human myeloblasts varying in anthracycline resistance. Cancer Lett 1984; 24: 305-309.
10. Marie J-P, Faussat-Suberville A-M, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993; 7: 825-831.
11. Nooter K, Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leukemia Res 1994; 18: 233-243.
12. Hegewisch-Becker S, Hossfeld DK. The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Ann Hematol 1996; 72: 105-117.
13. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997; 89: 3323-3329.
14. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Währer DCR, Ossenkoppele GJ, Schuurhuis GJ. Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 1997; 11: 1110-1118.
15. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fofo AT, Gascoyne RD, Head D, Houghton PJ, Kumar Srivastava D, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 3010-3020.
16. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Währer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B, Schuurhuis GJ. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996; 87: 4809-4816.
17. Marie J-P, Huet S, Faussat A-M, Perrot J-Y, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, Colosetti P, Cazin J-L, de Cremoux P, Delvincourt C, Demur C, Drenou B, Fennetau O, Feuillard J, Garnier-Suillerot A, Genne P, Gorisse M-C, Gosselin P, Joualt H, Lacave R, Le Calvez G, Léglise M-C, Léonce S, Manfait M, Maynadié M, Marle-Béral H, Merlin J-L, Mousseau M, Morjani H, Picard F, Pinguet F, Poncelet P, Racadot E, Raphael M, Richard B, Rossi J-F, Schlegel N, Vielh P, Zhou D-C, Robert J. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997; 11: 1086-1094.
18. Efferth T, Fabry U, Osieka R. Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997; 11: 1180-1186.
19. Kaspers GJ, Pieters R, van Zandwijk CH, de Laat PA, de Waal FC, van Wering ER, Veerman AJ. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from the bone marrow and peripheral blood. Br J Cancer 1991; 64: 469-474.
20. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464-2469.
21. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GI, Baak JPA, Eekman CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E, Pieters R, Lankelma J, Pinedo HM. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995; 1: 81-93.
22. Legrand O, Simonin G, Perrot J-Y, Zittoun R, Marie J-P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480-4488.
23. Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinical tumor samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 1996; 32A: 1024-1033.
24. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Tsuruo T, Pinedo HM, Lankelma J. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein. Biochem Pharmacol 1988; 37: 2389-2393.
25. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
26. Marie J-P. Editorial. Leukemia 1997; 11: 1065-1066.
27. Ross DD, Thompson BW, Ordón̄ez JV, Joneckis CC. Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content. Cytometry 1989; 10: 185-191.
28. Klumper E, Ossenkoppele GJ, Pieters R, Huismans DR, Loonen AH, Rottier A, Westra G, Veerman AJP. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukemia. Br J Haematol 1996; 93: 903-910.
29. Legrand O, Simonin G, Zittoun R, Marie J-P. In vitro drug resistance may help to predict in vivo response or resistance to chemotherapy in adult AML patients. Leukemia 1998; 12: 262 (Abstr.).
30. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner K, Pirker R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91: 1508-1513.
31. Solary E, Bidan J-M, Calvo F, Chauffert B, Caillot D, Mugneret F, Gauville C, Tsuruo T, Carli P-M, Guy H. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia 1991; 5: 592-597.
32. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, Broxterman HJ. Functional detection of MDR1/Pgp and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 1995; 72: 543-549.
33. Motomura S, Motoji T, Takanashi M, Wang Y-H, Shiozaki H, Sugawara I, Aikawa E, Tomida A, Tsuruo T, Kanda N, Mizoguchi H. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 1998; 91: 3163-3171.
34. Den Boer ML, Pieters R, Kazemier KM, Janka-Schaub GE, Henze G, Veerman AJP. The modulating effect of PSC833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia. Leukemia 1998; 12: 912-920.